RT
The startup develops therapeutic agents that activate key signaling pathways to enhance neurobehavioral function and cognitive performance in Alzheimer's patients. By improving memory and alleviating anxiety, these agents aim to slow disease progression and reduce behavioral symptoms associated with cognitive decline.
Updated 3 months ago
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops therapeutic agents that activate key signaling pathways to enhance neurobehavioral function and cognitive performance in Alzheimer's patients. By improving memory and alleviating anxiety, these agents aim to slow disease progression and reduce behavioral symptoms associated with cognitive decline.